ArticlePituitary2025
Clinical presentation, predictive factors and management of patients with Nelson syndrome: a retrospective study.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Corticotroph Tumour Progression 37 Years After Bilateral Adrenalectomy with Temozolomide-Naive Response to Pembrolizumab.Endocrine oncology (Bristol, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNelson syndrome (NS), or corticotroph tumor progression after bilateral adrenalectomy (CTP-BADX/NS), is a serious complication in patients with Cushing disease (CD) following BADX. Surgical tumor removal is the recommended treatment, though adjuvant therapies may be necessary. AIM OF THE STUDY: To evaluate clinical, radiological, and hormonal features of CD patients after BADX, identify risk factors for CTP-BADX/NS and assessed treatment outcome and cardio-metabolic complications.
methodsRetrospective study of 30 patients (male/female: 9/21; median age at CD diagnosis: 33 years, IQR 27-42) who underwent BADX and had a minimum follow-up of 18 months. Data were collected at diagnosis and during follow-up (6, 24 months and last visit).
resultsOver a median follow-up of 135 months, 9/30 patients (30%) developed NS, median 60 months after BADX. NS patients had earlier CD diagnosis and higher ACTH levels two years post-BADX [458 ng/L (IQR 245-723) vs. 146 ng/L (61-247), p = 0.020]. They also took lower fludrocortisone [0.05 mg/day vs. 0.1 mg/day, p = 0.001] and tended to use less hydrocortisone [20 mg/day [20-25] vs. 30 [25-30], p = 0.06]. Pre-BADX stereotactic radiosurgery (SRS) was more frequent in non-NS patients (52% vs. 22%, p = 0.11). Hypertension was more common in NS patients (78% vs 43%), but diabetes less so (33% vs 48%). In the CTP-BADX group, 6/9 required pituitary surgery and/or radiotherapy; medical therapy was used in 5 patients with varied results.
conclusionCTP-BADX/NS occurred in 30% of cases in our cohort. Higher ACTH post-BADX and younger age at CD onset may predict NS. No hormonal or radiological markers reliably predicted tumor progression. SRS before BADX and higher hydrocortisone doses might offer protection. Tumor control often needed a multimodal approach, with limited success from medical therapy alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.